File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fchem.2020.587207
- Scopus: eid_2-s2.0-85096370154
- PMID: 33240849
- WOS: WOS:000590548600001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands
Title | Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands |
---|---|
Authors | |
Keywords | gold(III) porphyrin N-heterocyclic carbene anticancer biomolecular target |
Issue Date | 2020 |
Publisher | Frontiers Media SA. The Journal's web site is located at http://www.frontiersin.org/chemistry |
Citation | Frontiers in Chemistry, 2020, v. 8, p. article no. 587207 How to Cite? |
Abstract | The use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in cisplatin, is of great interest but it is inherently unstable and redox-reactive under physiological conditions. Coordination ligands containing C and/or N donor atom(s) such as porphyrin, pincer-type cyclometalated and/or N-heterocyclic carbene (NHC) can be employed to stabilize gold(III) ion for the preparation of anticancer active compounds. In this review, we described our recent work on the anticancer properties of gold(III) compounds and the identification of molecular targets involved in the mechanisms of action. We also summarized the chemical formulation strategies that have been adopted for the delivery of cytotoxic gold compounds, and for ameliorating the in vivo toxicity. |
Persistent Identifier | http://hdl.handle.net/10722/302371 |
ISSN | 2023 Impact Factor: 3.8 2023 SCImago Journal Rankings: 0.818 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tong, KC | - |
dc.contributor.author | Hu, D | - |
dc.contributor.author | Wan, PK | - |
dc.contributor.author | Lok, CN | - |
dc.contributor.author | Che, CM | - |
dc.date.accessioned | 2021-09-06T03:31:20Z | - |
dc.date.available | 2021-09-06T03:31:20Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Frontiers in Chemistry, 2020, v. 8, p. article no. 587207 | - |
dc.identifier.issn | 2296-2646 | - |
dc.identifier.uri | http://hdl.handle.net/10722/302371 | - |
dc.description.abstract | The use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in cisplatin, is of great interest but it is inherently unstable and redox-reactive under physiological conditions. Coordination ligands containing C and/or N donor atom(s) such as porphyrin, pincer-type cyclometalated and/or N-heterocyclic carbene (NHC) can be employed to stabilize gold(III) ion for the preparation of anticancer active compounds. In this review, we described our recent work on the anticancer properties of gold(III) compounds and the identification of molecular targets involved in the mechanisms of action. We also summarized the chemical formulation strategies that have been adopted for the delivery of cytotoxic gold compounds, and for ameliorating the in vivo toxicity. | - |
dc.language | eng | - |
dc.publisher | Frontiers Media SA. The Journal's web site is located at http://www.frontiersin.org/chemistry | - |
dc.relation.ispartof | Frontiers in Chemistry | - |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | gold(III) | - |
dc.subject | porphyrin | - |
dc.subject | N-heterocyclic carbene | - |
dc.subject | anticancer | - |
dc.subject | biomolecular target | - |
dc.title | Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands | - |
dc.type | Article | - |
dc.identifier.email | Hu, D: hudi@HKUCC-COM.hku.hk | - |
dc.identifier.email | Che, CM: chemhead@hku.hk | - |
dc.identifier.authority | Lok, CN=rp00752 | - |
dc.identifier.authority | Che, CM=rp00670 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fchem.2020.587207 | - |
dc.identifier.pmid | 33240849 | - |
dc.identifier.pmcid | PMC7677586 | - |
dc.identifier.scopus | eid_2-s2.0-85096370154 | - |
dc.identifier.hkuros | 324864 | - |
dc.identifier.volume | 8 | - |
dc.identifier.spage | article no. 587207 | - |
dc.identifier.epage | article no. 587207 | - |
dc.identifier.isi | WOS:000590548600001 | - |
dc.publisher.place | Switzerland | - |